We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Akers Bio | AKR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 57.50 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 57.50 | 57.50 |
| Top Posts |
|---|
Posted at 27/7/2018 10:49 by algernon2 Yes this class action ongoing re investors who bought shares between certain dates should also include those who owned and held shares during those dates; as we held those shares rather than selling them , based on the same information or disinformation that the buyers may be suing Akers over.Discuss. I would (might have) have sold rather than held if I had access to accurate information and figures earlier; so I have sustained a loss here. Maybe the law firms looking at the issue could cast their nets a bit wider if they believe or can prove "evil" or "skullduggery" or "stupidity and laxness" has been at work. I shall send Akers the suggestion they respond via ADVFN BB to the comments if they have anything to say. |
Posted at 17/6/2018 18:20 by algernon2 How come there is a rns (see below) on Nasdaq but not yet on here?---------- "...The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akers Biosciences, Inc. ("Akers" or the "Company") (NASDAQ: AKER) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On May 21, 2018, Akers announced that it was unable to file its Form 10-Q quarterly report with the SEC for the period ending March 31, 2018. The Company added that its internal review has expanded to include the “characterizat If you are a shareholder who suffered a loss, click here to participate....." |
Posted at 17/1/2018 18:04 by buywell3 Anyone that buys this , with the Chart shape it hasIs a punter ... not an investor |
Posted at 21/3/2017 09:55 by wigwammer "You sure you're not Wally wigwammer?"Mcm - your friend made the same suggestion when I arrived on this board. Poorly researched and likely to cause conflict. You only have to check my posting history to know it is unlikely.I was interested here because i thought they had an attractive series of products, which were on the market albeit growing slowly, high margin, and the stock was on a low valuation. The evident criticism is that they were underpowered in the sales department, which (time will tell) appears to be being addressed. Your main criticism is Ray Akers - surely worthy of note therefore, that his name hasn't appeared in the last two RNS releases - yet, the Akers battering continues.I think my criticisms of this board recently are valid. It is misleading to emphasise unit sales with little reference to an 80% price hike. It is misleading to strike fear by suggesting cash from an issue isn't arriving, then not mentioning when it has arrived. The fact that my posts pointing these things out meets such hostility says a lot about the emotion investors have attached to this story - emotions can drive share prices but they are often distant from the truth.Re post 20... your friend then bought the shares?! Under the circumstances, where you say one thing one minute and do the opposite the next, it is likely you will be able to point to some success or other.Will be interesting to see if Ray Akers continues to be pushed into the background, or not.. |
Posted at 16/1/2017 10:38 by wigwammer "a constructive comment" (or at least something pertaining to knowledge of the company)Qaz - It was interesting to note in the last conference call that the breakeven level of sales had fallen from circa $7m to $4.6m pa, which implies cash burn has dropped from circa $80k pw to closer to $35k. This implies the newly raised cash may give them a 12-18 month window. Over that time it is possible they get traction on the wellness side - the market would, I suspect, richly reward even marginal success on this front, given a market cap of sub $10m.I'm disappointed management did not participate in the cash raise. It doesn't make a great deal of sense - even a token level of participation would have had an amplified impact on confidence. Perhaps they were limited for some reason or perhaps they intend purchasing in the after market. I think breath actuated tests are still a great idea - particularly when targeting a wellness market populated by health enthusiasts. With some medtechs the risk is getting the products to market - here, the risks are clearly related to trust. But nonetheless, if it works out from this valuation level and the risks are ameliorated, investors will be very well rewarded, imo dyor. |
Posted at 21/12/2016 13:22 by wigwammer In the event of a cash call it will be interesting to see if investors/management back the story here, or if those most in the know decide it is an utterly hopeless investment story (as they did, for example, with Clean Air Power). |
Posted at 21/12/2016 09:41 by norbus mcmOne can't do better than to listen to ramridge, a potential investor with no axe to grind like us oldies. AKR only owes me costs of a due diligence trip for 2 to NJ but otherwise a few bob profit on one small trade. I guess I am only here to see the finale when it comes. The survival now surely depends on China being real. |
Posted at 19/12/2016 17:09 by werewolfie I'm not tempted to invest again in Akers. They are a cautionary tale for inexperienced investors. |
Posted at 17/11/2016 11:11 by algernon2 "Akers Biosciences flags up fundraising plans"From Proactive Investors: "In a pre-emptory prospectus filed in the States, it has given itself the flexibility to issue common stock, preferred stock, warrants and/or units. Akers Biosciences flags up fundraising plans The company will use the money to grow the business. Akers Biosciences Inc (LON:AKR, NASDAQ:AKER), the UK and US listed rapid breath test specialist, has flagged up plans to raise up to US$7mln. In a pre-emptory prospectus filed in the States, it has given itself the flexibility to issue common stock, preferred stock, warrants and/or units. It says the proceeds will be put to work to grow the company, including bringing new products to the market. “We have not yet determined the amount of net proceeds to be used specifically for any of the foregoing purposes,” the document said. “Accordingly, our management will have significant discretion and flexibility in applying the net proceeds from this offering.”" |
Posted at 25/10/2016 09:07 by mcmather Looking to raise $7m. Registration fee will be £811k... (edit, minus about $810k...) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
